{"gene":"CBX7","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":2010,"finding":"CBX7 chromodomain binds both trimethylated histone H3K27me3 and the noncoding RNA ANRIL; both interactions are required for CBX7-mediated repression of the INK4b/ARF/INK4a locus. Structure-guided NMR analysis revealed the molecular interplay between RNA and H3K27me3 binding within the conserved chromodomain, and disruption of either interaction impairs senescence control.","method":"Co-IP, NMR structure, RNA-binding assays, chromodomain mutagenesis, ChIP, senescence assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 — structure-guided analysis with mutagenesis, multiple orthogonal methods in a single high-impact study","pmids":["20541999"],"is_preprint":false},{"year":2003,"finding":"CBX7 is a Polycomb group protein that interacts with Ring1, localizes to nuclear Polycomb bodies, and extends cellular lifespan by repressing the Ink4a/Arf locus through the p16(Ink4a)/Rb and Arf/p53 pathways; it does not co-localize or interact functionally with Bmi1.","method":"Genetic screen, Co-IP, shRNA knockdown, immunofluorescence localization, functional lifespan and growth assays","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal interaction data, direct localization, reverse-genetics with defined phenotype; foundational study with >260 citations","pmids":["14647293"],"is_preprint":false},{"year":2012,"finding":"Cbx7 is the primary PRC1 Polycomb ortholog in mouse embryonic stem cells (ESCs); it directly represses Cbx2, Cbx4, and Cbx8, and its expression is regulated by the miR-125 and miR-181 families. Cbx7 loss induces ESC differentiation while its ectopic expression inhibits differentiation and enhances self-renewal.","method":"Gain- and loss-of-function (KD/OE), ChIP, functional miRNA screen, differentiation assays, X-chromosome inactivation assays","journal":"Cell stem cell","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, replicated across multiple assays; >170 citations","pmids":["22226354"],"is_preprint":false},{"year":2012,"finding":"In mouse ESCs, Cbx7 (but not RYBP) is necessary for recruitment of Ring1B to chromatin; Cbx7-containing PRC1 complexes and RYBP-containing PRC1 complexes are mutually exclusive and regulate distinct gene sets, with Cbx7-occupied genes controlling early-lineage commitment.","method":"ChIP-seq, Co-IP, siRNA knockdown, Ring1B chromatin fractionation, gene expression profiling","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP, ChIP-seq, and genetic KD with defined molecular phenotype; >160 citations","pmids":["23273917"],"is_preprint":false},{"year":2007,"finding":"Cbx7 initiates T cell lymphomagenesis in mice and cooperates with c-Myc to produce B cell lymphomas; it represses the Ink4a/Arf locus and acts epistatically upstream of the Arf-p53 pathway during tumorigenesis.","method":"Transgenic mouse model (lymphoid-targeted Cbx7 expression), genetic epistasis, tumor analysis, Ink4a/Arf expression assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic epistasis with defined tumor phenotype; >140 citations","pmids":["17374722"],"is_preprint":false},{"year":2012,"finding":"CBX7 acts as a tumor suppressor by binding to the CCNE1 (cyclin E) promoter in a complex with HDAC2 to negatively regulate cyclin E expression; Cbx7-knockout mice develop liver and lung adenomas and carcinomas, with upregulated cyclin E.","method":"Cbx7-KO mouse generation, ChIP, Co-IP with HDAC2, gene expression analysis in KO MEFs and tumors, in vivo/in vitro assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 — KO mouse model, ChIP demonstrating direct promoter binding, co-IP identifying HDAC2 complex; >125 citations","pmids":["22214847"],"is_preprint":false},{"year":2015,"finding":"The CBX7 chromodomain binds H3K27me3 through an aromatic cage; small molecules (MS37452) that occupy the methyl-lysine binding pocket competitively inhibit this interaction and derepress p16/CDKN2A in prostate cancer cells by displacing CBX7 from the INK4A/ARF locus.","method":"Crystal structures of CBX7ChD-ligand complexes, fluorescence polarization binding assays, ChIP in prostate cancer cells","journal":"Chemistry & biology","confidence":"High","confidence_rationale":"Tier 1 — crystal structures with functional cellular validation; >97 citations","pmids":["25660273"],"is_preprint":false},{"year":2016,"finding":"Live-cell single-molecule tracking revealed that Cbx7 is targeted to chromatin by co-recognition of H3K27me3 and DNA; biochemical analysis identified an AT-hook-like (ATL) motif that, together with the chromodomain, constitutes a functional DNA-binding unit. Disrupting PRC1 complex formation facilitates Cbx7 chromatin targeting.","method":"Live-cell single-molecule tracking (SMT), genetic engineering of Cbx7 mutants, biochemical DNA-binding assays, CRISPR-based H3K27me3 disruption","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1-2 — live-cell SMT combined with mutagenesis and biochemical assays; >94 citations","pmids":["27723458"],"is_preprint":false},{"year":2014,"finding":"Peptidomimetic inhibitors of CBX7 targeting the H3K27me3-binding chromodomain were developed; NMR and X-ray crystal structures of ligand-chromodomain complexes revealed a structural motif unique to CBX7 among human CBX proteins, enabling ~200 nM potency with 10-fold selectivity over CBX8.","method":"Fluorescence polarization, isothermal titration calorimetry, 2D NMR, X-ray crystallography","journal":"Journal of medicinal chemistry","confidence":"High","confidence_rationale":"Tier 1 — crystal structure and NMR with quantitative binding characterization","pmids":["24625057"],"is_preprint":false},{"year":2009,"finding":"CBX7 associates with DNA methyltransferase (DNMT) enzymes and can initiate stable epigenetic silencing of genes frequently hypermethylated in cancer. In embryonal carcinoma cells, CBX7 promotes DNMT assembly at target gene promoters and initiates DNA hypermethylation.","method":"Co-IP (CBX7-DNMT complex), ChIP, shRNA knockdown, gene expression and methylation assays in EC cells","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP and ChIP showing DNMT recruitment, but complex formation characterized only by single-lab pulldown","pmids":["19602592"],"is_preprint":false},{"year":2010,"finding":"CBX7 directly initiates H3K9me3 formation at the p16 promoter by forming a complex with the methyltransferase SUV39H2; this interaction was demonstrated by bimolecular fluorescence complementation and co-IP, and requires an intact chromodomain and Pc-box. siRNA knockdown of Suv39h2 blocks CBX7-mediated p16 repression.","method":"Co-IP, bimolecular fluorescence complementation (BiFC), ChIP, siRNA knockdown, CBX7 chromodomain/Pc-box mutants","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — BiFC and Co-IP with genetic validation by mutagenesis and siRNA; single lab","pmids":["21060834"],"is_preprint":false},{"year":2013,"finding":"MAPK signaling phosphorylates Cbx7 at Thr-118 (near the conserved Polycomb box); this phosphorylation, detected by a site-specific antibody and mass spectrometry, moderately enhances p16 repression and is induced upon EGF stimulation, which also triggers robust interaction of Cbx7 with other PRC1 members.","method":"Mass spectrometry, site-specific antibody, MEK inhibitor treatment, Co-IP after EGF stimulation, RAS-induced senescence assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — MS identification + site-specific antibody + functional mutagenesis + epistasis in senescence model","pmids":["24194518"],"is_preprint":false},{"year":2017,"finding":"dCLIP (denaturing CLIP) showed that CBX7 predominantly binds 3' UTRs of messenger RNAs with a median footprint of ~171-183 nucleotides. Four families of consensus RNA-binding motifs were identified; their mutation abolishes CBX7 binding in vitro. Antisense oligonucleotide (ASO) intervention paradoxically increases CBX7 binding and enhances gene expression.","method":"dCLIP-seq (UV crosslink immunoprecipitation with denaturation), bioinformatics motif analysis, in vitro binding with mutant motifs, ASO treatment","journal":"Cell systems","confidence":"High","confidence_rationale":"Tier 1-2 — genome-wide CLIP with motif mutagenesis validation in vitro; independently validated in mouse and human","pmids":["29073373"],"is_preprint":false},{"year":2019,"finding":"CBX7 interacts non-canonically with H3K9 methyltransferases SETDB1, EHMT1, and EHMT2 (which contain trimethylated lysine motifs similar to H3K27me3); mass spectrometry identified these interactions, and depletion of SETDB1 in AML cells phenocopies CBX7 repression, establishing a non-canonical crosstalk pathway that controls HSPC self-renewal.","method":"Mass spectrometry interactome, Co-IP, genetic depletion (shRNA), AML cell proliferation and differentiation assays, xenotransplantation","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — MS-based interactome confirmed by Co-IP, with epistasis via SETDB1 KD phenocopying CBX7; multiple orthogonal methods","pmids":["30759399"],"is_preprint":false},{"year":2019,"finding":"A positive allosteric modulator (PAM) peptidomimetic UNC4976 simultaneously antagonizes H3K27me3-specific recruitment of CBX7 to target genes while increasing non-specific binding to DNA and RNA, thereby reequilibrating PRC1 away from H3K27me3-marked regions. This reveals that CBX7 nucleic acid binding and histone binding are allosterically coupled.","method":"Quantitative cellular assay, fluorescence polarization, three orthogonal cellular assays, ChIP","journal":"Cell chemical biology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple cellular assays with mechanistic interpretation; single lab","pmids":["31422906"],"is_preprint":false},{"year":2016,"finding":"Structure-guided discovery identified Class A CBX7 chromodomain antagonists that inhibit methyl-lysine binding and Class B compounds (MS351) that inhibit H3K27me3 binding when CBX7 is bound to RNA. Crystal structure of CBX7ChD/MS351 reveals ligand recognition by aromatic cage residues that engage methyl-lysine. MS351 induces transcriptional derepression of p16(INK4a) in ESCs and prostate cancer cells.","method":"Crystal structure of CBX7ChD/MS351 complex, fluorescence polarization, ChIP, gene expression assays","journal":"ACS medicinal chemistry letters","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with functional cellular validation by ChIP and gene expression","pmids":["27326334"],"is_preprint":false},{"year":2014,"finding":"CBX7 inhibits breast tumorigenicity by increasing DKK-1 transcription through cooperation with p300 acetyltransferase, enhancing histone acetylation at the DKK-1 promoter, thereby suppressing Wnt/β-catenin/TCF signaling. Pharmacological DKK-1 inhibition reverses CBX7-mediated Wnt suppression.","method":"ChIP (histone acetylation at DKK-1 promoter), Co-IP (CBX7-p300), luciferase reporter assay, shRNA KD, pharmacological inhibitor rescue, in vivo tumor initiation assay","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and Co-IP with functional rescue; single lab","pmids":["25351982"],"is_preprint":false},{"year":2020,"finding":"CBX7 binds the E-box and prevents TWIST-1 from binding its transcriptional targets in secondary epithelial ovarian cancer cells; deletion of CBX7 is sufficient to reactivate TWIST-1-induced transcription and restore mesenchymal transformation and tumorigenicity.","method":"CBX7 deletion (CRISPR/genetic), E-box binding assay, in vitro and in vivo tumorigenicity assays, EMT marker analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — defined molecular mechanism (E-box competition) with in vivo phenotype; single lab","pmids":["32205869"],"is_preprint":false},{"year":2016,"finding":"CBX7 represses YAP/TAZ-dependent transcription in glioma cells, leading to downregulation of CTGF and reduced phospho-JNK; CBX7 overexpression inhibits cell migration, and migration inhibition is reversed by exogenous CTGF or constitutively active JNK. Cbx7 promoter is hypermethylated in GBM.","method":"GSEA of CBX7-regulated genes, Western blot (YAP/TAZ, CTGF, pJNK), exogenous CTGF rescue, constitutively active JNK rescue, bisulfite sequencing","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2-3 — pathway placement by epistasis with rescue experiments; single lab","pmids":["27291091"],"is_preprint":false},{"year":2021,"finding":"CBX7 suppresses AKR1B10 transcription in a PRC1-dependent manner in bladder cancer cells; loss of CBX7 leads to AKR1B10 upregulation that activates ERK signaling. This was established by RNA-seq and ChIP assays identifying AKR1B10 as a direct downstream target.","method":"RNA-seq, ChIP, siRNA knockdown, small molecule inhibitor (oleanolic acid), in vivo tumor model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP confirming direct targeting, RNA-seq, and functional rescue; single lab","pmids":["34035231"],"is_preprint":false},{"year":2023,"finding":"CBX7 interacts with TARDBP (TDP-43) and positively regulates its downstream target RBM38 in a TARDBP-dependent manner; this axis mediates CBX7-directed cell cycle exit of postnatal cardiomyocytes. Genetic inactivation of Cbx7 in cardiomyocytes increased proliferation, impeded cardiac maturation, and promoted heart regeneration after injury.","method":"Co-immunoprecipitation, mass spectrometry, conditional cardiac KO mice (Tnnt2-Cre and Myh6-MCM), adenoviral OE, neonatal apical resection and adult MI models, proliferation marker immunostaining","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 1-2 — MS-identified interaction confirmed by Co-IP, conditional KO with multiple cardiac phenotypes, epistasis via RBM38 OE rescue","pmids":["37158107"],"is_preprint":false},{"year":2020,"finding":"Two CBX7 isoforms (p36 and p22) have distinct subcellular localizations and opposing roles: p36CBX7 localizes to the nucleus and is expressed in proliferating cells, whereas p22CBX7 localizes to the cytoplasm, is induced by serum starvation, and inhibits cell proliferation.","method":"Subcellular fractionation, immunofluorescence, serum starvation experiments, proliferation assays","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2-3 — direct localization by fractionation and imaging, with functional consequence; single lab","pmids":["32415167"],"is_preprint":false},{"year":2018,"finding":"CBX7 regulates axon growth and regeneration in neurons; knockdown of CBX7 in embryonic cortical neurons or adult DRG neurons enhances axon growth ability. GATA4 and SOX11 are functional downstream transcriptional targets of CBX7 in controlling axon regeneration; knockdown of GATA4 or SOX11 inhibits CBX7-knockdown-induced axon regeneration.","method":"CBX7 shRNA KD in primary neurons, DRG axon regeneration assays, genetic epistasis (GATA4/SOX11 KD rescue)","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis with defined downstream targets and functional axon phenotype; single lab","pmids":["29459770"],"is_preprint":false},{"year":2022,"finding":"RNF26 acts as an E3 ubiquitin ligase that promotes ubiquitination and proteasomal degradation of CBX7 protein (without affecting CBX7 mRNA), thereby activating the TNF/ETS1 signaling pathway to promote ccRCC growth.","method":"Co-IP, ubiquitination assay, cycloheximide chase (protein stability), shRNA/OE, xenograft mouse model","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP, ubiquitination assay, and stability assay identifying RNF26 as E3 ligase; single lab","pmids":["35342353"],"is_preprint":false},{"year":2022,"finding":"EZH2 represses CBX7 expression by increasing H3K27me3 at the CBX7 locus in bladder cancer cells; CBX7 in turn directly downregulates FGFR3 expression (confirmed by ChIP) and sensitizes bladder cancer cells to cisplatin by inactivating the PI3K/AKT signaling pathway.","method":"ChIP-qPCR (H3K27me3 at CBX7 locus; CBX7 binding at FGFR3 promoter), Western blot, RT-qPCR, CCK-8, xenograft model","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP confirming direct regulation in both directions; single lab","pmids":["36396821"],"is_preprint":false},{"year":2024,"finding":"RNF2 promotes ubiquitination and proteasomal degradation of CBX7 protein (without affecting CBX7 mRNA); knockdown of RNF2 upregulates CBX7 and reduces chondrosarcoma cell proliferation, migration, and angiogenesis, effects reversed by CBX7 knockdown.","method":"Co-IP, ubiquitination assay, cycloheximide chase, siRNA/OE, xenograft mouse model","journal":"Cancer & metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — ubiquitination and stability assays with in vivo validation; single lab","pmids":["39456039"],"is_preprint":false},{"year":2019,"finding":"HIF-1α transcriptionally activates CBX7 expression during hypoxia/ischemia, and this HIF-1α-CBX7 cascade modulates neural progenitor cell (NPC) proliferation; CBX7-knockout mice generated by CRISPR/Cas9 show significantly reduced NPC numbers.","method":"ChIP (HIF-1α at CBX7 promoter), CRISPR/Cas9 KO mice, NPC proliferation assays, hypoxia model","journal":"Neuropathology and applied neurobiology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP identifying direct transcriptional regulation, CRISPR KO phenotype; single lab","pmids":["31630421"],"is_preprint":false},{"year":2024,"finding":"CBX7 promotes meningioma progression control by transcriptionally repressing USP44, a deubiquitinase for c-MYC; loss of CBX7 leads to USP44-mediated c-MYC stabilization, increased LDHA transactivation, and enhanced glycolysis. Restoration of CBX7 triggers a metabolic shift from glycolysis to oxidative phosphorylation.","method":"iTRAQ proteomics, ChIP, luciferase reporter assay, siRNA/OE, subcutaneous and orthotopic xenograft models","journal":"Journal of molecular cell biology","confidence":"Medium","confidence_rationale":"Tier 2 — proteomics plus ChIP and reporter assay identifying USP44/c-MYC/LDHA pathway; single lab","pmids":["37791390"],"is_preprint":false},{"year":2026,"finding":"CBX7 preferentially binds Ser31-phosphorylated H3.3K27me3 nucleosomes and recruits KAP1, which engages histone lysine 9 methyltransferase to establish H3K9me3-associated heterochromatin. Disrupting the H3.3-CBX7 interaction significantly impairs H3K9me3 and activates retrotransposons; the same axis is required for H3K9me2/3 accumulation at the inactive X during X-chromosome inactivation.","method":"Biochemical nucleosome binding assays, Co-IP (CBX7-KAP1), ChIP-seq (H3K9me3), retrotransposon activation assays, X-inactivation analysis with H3.3-CBX7 interaction-blocking mutations","journal":"Science bulletin","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including biochemical reconstitution, Co-IP, ChIP-seq, and genetic disruption with defined mechanistic readouts","pmids":["41582043"],"is_preprint":false},{"year":2026,"finding":"CBX7 forms a methylation-dependent transcriptional activation complex at cytokine gene promoters (unexpectedly inducing transcription) and also translocates to the cytosol where it forms a methylation-dependent signaling complex with c-Raf, MEK1/2, and CK2-α to generate sustained ERK1/2 signaling in lymphoid cells; both activities are absent in epithelial cells.","method":"Co-IP (CBX7-c-Raf, MEK1/2, CK2-α), ChIP (CBX7 at cytokine promoters), RNA-seq, genetic KO and pharmacological inhibition in mouse and human lymphoid cells, allergic asthma mouse models","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 1-2 — Co-IP, ChIP, RNA-seq, and in vivo genetic/pharmacological validation across multiple model systems","pmids":["41686891"],"is_preprint":false},{"year":2024,"finding":"In aged hearts, CBX7 forms liquid-liquid phase separation (LLPS) with ATP7A, trapping ATP7A intracellularly and reducing copper efflux, thereby triggering cuproptosis; a small-molecule inhibitor (δ-Amyrenone) that disrupts CBX7-ATP7A LLPS restores ATP7A trafficking and improves cardiac function.","method":"LLPS assay, protein interaction assay (CBX7-ATP7A), single-cell RNA-seq, high-throughput screening, in vivo mouse and minipig MI models","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 — LLPS and protein interaction data with in vivo validation; novel mechanism, single lab","pmids":["41117088"],"is_preprint":false},{"year":2022,"finding":"Exosomal circ_0006790 facilitates nuclear translocation of CBX7; nuclear CBX7 then recruits DNA methyltransferases to the S100A11 promoter to increase S100A11 DNA methylation and suppress its transcription, thereby inhibiting PDAC immune escape.","method":"Exosome treatment, nuclear fractionation, ChIP (DNMT recruitment to S100A11 promoter), siRNA KD of CBX7, rescue with S100A11 OE","journal":"American journal of cancer research","confidence":"Medium","confidence_rationale":"Tier 2-3 — ChIP showing DNMT recruitment, fractionation, and functional rescue; single lab","pmids":["35693076"],"is_preprint":false},{"year":2025,"finding":"DNMT1 methylates the CBX7 promoter to suppress CBX7 expression in PDAC; silencing DNMT1 upregulates CBX7, which reduces ERK phosphorylation and suppresses tumor progression. ChIP and dual-luciferase assays confirmed direct DNMT1 binding and methylation of the CBX7 promoter.","method":"ChIP-qPCR (DNMT1 at CBX7 promoter), dual-luciferase reporter assay, siRNA knockdown, Western blot, CCK-8, wound healing, transwell assays","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and reporter assay confirming direct regulation; single lab","pmids":["40387566"],"is_preprint":false},{"year":2024,"finding":"CBX7 inhibition by small molecules abolishes CBX7 interaction with H3K9 methyltransferases EHMT1/2 and SETDB1, reduces H3K9 methylation, reactivates target gene expression, and has additive effects with EHMT1/2 or SETDB1 inhibitors on reducing leukemic cell growth and inducing differentiation.","method":"Co-IP (CBX7-EHMT1/2-SETDB1), pharmacological CBX7 inhibition, H3K9 methylation ChIP, gene expression assays, cell proliferation and differentiation assays","journal":"Experimental hematology","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP and ChIP with pharmacological intervention; single lab","pmids":["39613290"],"is_preprint":false}],"current_model":"CBX7 is a PRC1 Polycomb group protein whose N-terminal chromodomain binds H3K27me3 (and, co-operatively, DNA via an AT-hook-like motif and noncoding RNA such as ANRIL) to repress target loci including INK4a/ARF; it recruits Ring1B and forms complexes with HDAC2, DNMTs, SUV39H2, and non-canonically with H3K9 methyltransferases SETDB1/EHMT1/EHMT2; its activity is modulated by MAPK-mediated phosphorylation (Thr-118), ubiquitin-mediated degradation by E3 ligases RNF2 and RNF26, and by HIF-1α-driven transcription; cell-type-specifically it can also act as a transcriptional activator and cytosolic ERK signaling scaffold in lymphoid cells, and in cardiomyocytes it interacts with TARDBP to regulate RBM38-dependent cell cycle exit."},"narrative":{"teleology":[{"year":2003,"claim":"Establishing CBX7 as a Polycomb group protein that extends replicative lifespan by repressing Ink4a/Arf resolved the question of which PcG protein directly silences this senescence-controlling locus independently of Bmi1.","evidence":"Co-IP with Ring1, immunofluorescence to Polycomb bodies, shRNA knockdown with growth/lifespan assays in human fibroblasts","pmids":["14647293"],"confidence":"High","gaps":["Genome-wide targets beyond Ink4a/Arf not identified","Mechanism of chromatin recruitment not resolved","How CBX7 and Bmi1 complexes partition was unclear"]},{"year":2007,"claim":"Demonstrating that Cbx7 overexpression initiates T-cell lymphoma and cooperates with c-Myc in B-cell lymphoma established CBX7 as an oncogene acting epistatically upstream of Arf-p53, resolving whether its Ink4a/Arf repression was tumorigenic in vivo.","evidence":"Lymphoid-targeted Cbx7 transgenic mice, genetic epistasis with Ink4a/Arf deletion and p53 pathway","pmids":["17374722"],"confidence":"High","gaps":["Whether CBX7 has tumor-suppressive roles in other tissues was unknown","Mechanism of tissue-specific oncogenicity unclear"]},{"year":2009,"claim":"Identifying CBX7 association with DNA methyltransferases showed that PRC1 can initiate stable DNA hypermethylation at target promoters, linking Polycomb silencing to permanent epigenetic memory.","evidence":"Co-IP of CBX7-DNMT complexes, ChIP and methylation analysis in embryonal carcinoma cells","pmids":["19602592"],"confidence":"Medium","gaps":["DNMT interaction characterized by single-lab pulldown only","Which DNMT isoform is principally recruited was not resolved","Genome-wide extent of CBX7-dependent DNA methylation unknown"]},{"year":2010,"claim":"Structural and biochemical dissection of the CBX7 chromodomain revealed dual recognition of H3K27me3 and ANRIL ncRNA, answering how CBX7 achieves locus-specific targeting at INK4a/ARF through combinatorial chromatin and RNA readout.","evidence":"NMR structure of chromodomain, RNA-binding assays, chromodomain mutagenesis, ChIP and senescence assays","pmids":["20541999"],"confidence":"High","gaps":["Which other ncRNAs contribute to CBX7 targeting was unknown","Relative contributions of RNA vs. histone binding to genome-wide occupancy not quantified"]},{"year":2010,"claim":"Discovery that CBX7 recruits SUV39H2 to deposit H3K9me3 at the p16 promoter revealed a PRC1-H3K9 methylation crosstalk mechanism, expanding the epigenetic toolkit downstream of CBX7 beyond canonical PRC1 activities.","evidence":"BiFC, Co-IP, ChIP, and siRNA knockdown of Suv39h2 in human cells","pmids":["21060834"],"confidence":"Medium","gaps":["Single-lab observation without independent replication","Whether SUV39H2 interaction is direct or mediated by other PRC1 subunits unclear"]},{"year":2012,"claim":"Three contemporaneous studies established Cbx7 as the dominant PRC1 chromodomain subunit in ESCs—required for Ring1B chromatin recruitment, self-renewal maintenance, and repression of lineage-commitment genes and alternative Cbx paralogs—resolving how PRC1 composition is specified in pluripotent cells.","evidence":"ChIP-seq, Co-IP, siRNA/overexpression, miRNA screens, differentiation assays in mouse ESCs; Cbx7-KO mouse with liver/lung carcinomas and HDAC2 Co-IP","pmids":["22226354","23273917","22214847"],"confidence":"High","gaps":["How Cbx7-to-Cbx2/4 switching is executed during differentiation was not mechanistically resolved","Whether Cbx7-PRC1 and RYBP-PRC1 co-occupy any loci was untested"]},{"year":2013,"claim":"Identification of MAPK-mediated phosphorylation at Thr-118 showed that extracellular signals dynamically modulate CBX7's PRC1 interactions and repressive activity, answering how CBX7 function is tuned by signaling inputs.","evidence":"Mass spectrometry, phospho-specific antibody, MEK inhibitor treatment, Co-IP after EGF stimulation, RAS-induced senescence assay","pmids":["24194518"],"confidence":"High","gaps":["Whether other kinases phosphorylate CBX7 was unknown","Effect of Thr-118 phosphorylation on chromatin occupancy genome-wide not tested"]},{"year":2014,"claim":"Development of peptidomimetic inhibitors with crystal structures of the CBX7 chromodomain–ligand complexes provided the first chemical tools to probe CBX7 function and revealed structural features unique to CBX7 among human CBX paralogs, enabling selective pharmacological perturbation.","evidence":"X-ray crystallography, NMR, fluorescence polarization, isothermal titration calorimetry","pmids":["24625057","25660273"],"confidence":"High","gaps":["Cell permeability and in vivo efficacy of early compounds not established","Whether inhibitors affect CBX7-RNA interactions was untested"]},{"year":2016,"claim":"Live-cell single-molecule tracking combined with biochemical analysis identified an AT-hook-like motif that cooperates with the chromodomain for DNA binding, establishing that CBX7 chromatin targeting requires bivalent histone-DNA co-recognition rather than H3K27me3 alone.","evidence":"Single-molecule tracking, CRISPR-mediated H3K27me3 ablation, DNA-binding assays with CBX7 mutants","pmids":["27723458"],"confidence":"High","gaps":["Sequence specificity of DNA binding not fully resolved","How ATL motif integrates with RNA binding was unclear"]},{"year":2017,"claim":"Genome-wide dCLIP revealed that CBX7 binds predominantly to mRNA 3′ UTRs via defined consensus motifs, uncovering an unexpected post-transcriptional dimension of CBX7 function beyond canonical chromatin silencing.","evidence":"dCLIP-seq with motif mutagenesis validation in vitro, ASO intervention in mouse and human cells","pmids":["29073373"],"confidence":"High","gaps":["Functional consequence of mRNA binding on translation/stability not determined for most targets","Whether mRNA binding occurs in the nucleus, cytoplasm, or both was not resolved"]},{"year":2019,"claim":"Mass spectrometry-based interactomics revealed that CBX7 non-canonically engages H3K9 methyltransferases SETDB1, EHMT1, and EHMT2 via their trimethylated lysine motifs, establishing a PRC1-H3K9me crosstalk axis critical for HSPC self-renewal in AML.","evidence":"MS interactome, Co-IP, shRNA depletion phenocopying in AML cells, xenotransplantation","pmids":["30759399"],"confidence":"High","gaps":["Whether CBX7 chromodomain directly reads methylated lysines on SETDB1/EHMTs or requires an adaptor was unclear","Contribution of this axis to normal hematopoiesis vs. leukemogenesis not separated"]},{"year":2019,"claim":"A positive allosteric modulator (UNC4976) demonstrated that CBX7's histone-binding and nucleic-acid-binding activities are allosterically coupled, establishing a pharmacological principle for redistributing PRC1 away from H3K27me3-marked loci.","evidence":"Fluorescence polarization, three orthogonal cellular assays, ChIP","pmids":["31422906"],"confidence":"Medium","gaps":["Single-lab observation","In vivo effects of allosteric modulation not tested","Structural basis of allosteric coupling not resolved"]},{"year":2020,"claim":"Identification of two CBX7 isoforms (p36/nuclear, p22/cytoplasmic) with opposing effects on proliferation revealed that alternative isoform usage partitions CBX7 between chromatin repression and cytoplasmic functions.","evidence":"Subcellular fractionation, immunofluorescence, serum-starvation induction, proliferation assays","pmids":["32205869","32415167"],"confidence":"Medium","gaps":["Molecular determinants of isoform switching unknown","Cytoplasmic binding partners of p22 not identified","Whether p22 retains RNA-binding capacity untested"]},{"year":2022,"claim":"Discovery that RNF26 ubiquitinates CBX7 for proteasomal degradation identified the first E3 ligase controlling CBX7 protein turnover, explaining how CBX7 levels are post-translationally tuned in renal cell carcinoma.","evidence":"Co-IP, ubiquitination assay, cycloheximide chase, xenograft model","pmids":["35342353"],"confidence":"Medium","gaps":["Single-lab observation","Ubiquitination site(s) on CBX7 not mapped","Whether RNF26-mediated degradation operates in normal tissues unknown"]},{"year":2023,"claim":"Identification of the CBX7–TARDBP–RBM38 axis in cardiomyocytes established a non-canonical mechanism by which CBX7 enforces postnatal cell-cycle exit, answering why Cbx7 loss permits cardiomyocyte proliferation and heart regeneration after injury.","evidence":"Co-IP, mass spectrometry, conditional cardiac KO mice (Tnnt2-Cre and Myh6-MCM), neonatal and adult injury models","pmids":["37158107"],"confidence":"High","gaps":["Whether the CBX7-TARDBP interaction is chromodomain-dependent or Pc-box-dependent not resolved","How this axis interfaces with canonical PRC1 silencing in cardiomyocytes unknown"]},{"year":2024,"claim":"Discovery that CBX7 undergoes liquid-liquid phase separation with ATP7A, trapping the copper transporter intracellularly and triggering cuproptosis in aged hearts, revealed a previously unrecognized biophysical mechanism linking CBX7 to copper homeostasis and cardiac aging.","evidence":"LLPS assay, protein interaction assay, scRNA-seq, high-throughput compound screening, mouse and minipig MI models","pmids":["41117088"],"confidence":"Medium","gaps":["Single-lab finding; LLPS mechanism not reconstituted with purified components","Whether other PRC1 subunits participate in or modulate LLPS unknown","Generalizability beyond cardiac tissue untested"]},{"year":2024,"claim":"Pharmacological CBX7 inhibition abolished interactions with EHMT1/2 and SETDB1 and showed additive anti-leukemic effects with H3K9 methyltransferase inhibitors, validating the CBX7-H3K9me axis as a druggable node in AML.","evidence":"Co-IP, H3K9me ChIP, pharmacological inhibition, proliferation/differentiation assays in leukemic cells","pmids":["39613290"],"confidence":"Medium","gaps":["In vivo pharmacokinetics and efficacy not reported","Whether inhibitor selectivity among CBX paralogs is sufficient for therapeutic use unknown"]},{"year":2026,"claim":"Biochemical and ChIP-seq studies showed CBX7 preferentially reads Ser31-phosphorylated H3.3K27me3, recruiting KAP1 and H3K9 methyltransferase to establish heterochromatin and silence retrotransposons; this axis is also required for H3K9me2/3 accumulation on the inactive X chromosome, unifying CBX7's heterochromatin roles across developmental contexts.","evidence":"Nucleosome binding assays, Co-IP (CBX7-KAP1), ChIP-seq (H3K9me3), retrotransposon reactivation, X-inactivation assays with interaction-blocking mutations","pmids":["41582043"],"confidence":"High","gaps":["Which kinase deposits Ser31 phosphorylation to prime CBX7 recruitment is unknown","Structural basis of Ser31-phospho recognition by CBX7 not determined"]},{"year":2026,"claim":"Discovery that CBX7 functions as both a transcriptional activator and a cytoplasmic ERK-signaling scaffold in lymphoid (but not epithelial) cells fundamentally expanded the functional repertoire of PRC1 subunits, revealing cell-type-specific non-canonical roles.","evidence":"Co-IP (CBX7–c-Raf, MEK1/2, CK2-α), ChIP at cytokine promoters, RNA-seq, genetic KO and pharmacological inhibition in lymphoid cells, allergic asthma mouse models","pmids":["41686891"],"confidence":"High","gaps":["What determines the switch from repressor to activator in lymphoid cells is unknown","Whether the cytoplasmic signaling role requires the p22 isoform specifically is untested"]},{"year":null,"claim":"Key open questions include: the structural basis for allosteric coupling between histone, DNA, and RNA binding; how cell-type-specific isoform usage and post-translational modifications partition CBX7 between canonical PRC1 silencing, transcriptional activation, cytoplasmic signaling, and phase-separation functions; and whether pharmacological targeting of CBX7 can achieve paralog selectivity sufficient for therapeutic use in cancer or cardiac regeneration.","evidence":"","pmids":[],"confidence":"Low","gaps":["No full-length CBX7 structure exists","Isoform-specific interactomes not systematically compared","In vivo efficacy of CBX7 inhibitors not demonstrated in disease models"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[0,6,7,8,14,15,28]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[0,12,14]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[7,17]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,5,16,19,27,29]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[29]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[29,20]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,21,31]},{"term_id":"GO:0005694","term_label":"chromosome","supporting_discovery_ids":[3,7,28]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[21,29]}],"pathway":[{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[0,3,7,10,28]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[1,5,20]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[5,16,19,27,29]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[11,18,29]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[2,3,22]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[1,4]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[29]}],"complexes":["PRC1 (Cbx7-Ring1B canonical PRC1)","CBX7-HDAC2 repressive complex","CBX7-SETDB1/EHMT1/EHMT2 complex","CBX7-c-Raf/MEK1/2/CK2-α cytoplasmic signaling complex"],"partners":["RING1","RNF2","HDAC2","SETDB1","EHMT1","EHMT2","TARDBP","KAP1"],"other_free_text":[]},"mechanistic_narrative":"CBX7 is a Polycomb Repressive Complex 1 (PRC1) subunit that functions as a multivalent chromatin reader integrating histone, DNA, and RNA recognition to enforce transcriptional silencing at developmental and tumor-suppressor loci, while also exhibiting cell-type-specific roles as a transcriptional activator and cytoplasmic signaling scaffold. Its N-terminal chromodomain recognizes H3K27me3 (preferentially on Ser31-phosphorylated H3.3 nucleosomes) through an aromatic cage, and an adjacent AT-hook-like motif cooperatively binds DNA; the chromodomain also engages noncoding RNA (ANRIL) and mRNA 3′ UTRs, with nucleic-acid and histone binding allosterically coupled [PMID:20541999, PMID:27723458, PMID:29073373, PMID:41582043]. CBX7 recruits Ring1B to chromatin in embryonic stem cells to maintain pluripotency and repress early-lineage genes, while at other loci it assembles repressive complexes containing HDAC2, DNMTs, SUV39H2, or the H3K9 methyltransferases SETDB1/EHMT1/EHMT2 to silence targets including INK4a/ARF, CCNE1, and FGFR3 [PMID:23273917, PMID:22214847, PMID:19602592, PMID:21060834, PMID:30759399]. CBX7 protein stability is regulated by ubiquitin-dependent proteasomal degradation mediated by E3 ligases RNF26 and RNF2, and its activity is modulated by MAPK-mediated Thr-118 phosphorylation; in lymphoid cells, CBX7 unexpectedly translocates to the cytosol to form a methylation-dependent signaling complex with c-Raf, MEK1/2, and CK2-α that sustains ERK signaling, while in cardiomyocytes it interacts with TARDBP to regulate RBM38-dependent cell-cycle exit [PMID:35342353, PMID:39456039, PMID:24194518, PMID:41686891, PMID:37158107]."},"prefetch_data":{"uniprot":{"accession":"O95931","full_name":"Chromobox protein homolog 7","aliases":[],"length_aa":251,"mass_kda":28.3,"function":"Component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development. PcG PRC1 complex acts via chromatin remodeling and modification of histones; it mediates monoubiquitination of histone H2A 'Lys-119', rendering chromatin heritably changed in its expressibility. Promotes histone H3 trimethylation at 'Lys-9' (H3K9me3). Binds to trimethylated lysine residues in histones, and possibly also other proteins. Regulator of cellular lifespan by maintaining the repression of CDKN2A, but not by inducing telomerase activity","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/O95931/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CBX7","classification":"Not Classified","n_dependent_lines":7,"n_total_lines":1208,"dependency_fraction":0.005794701986754967},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CBX7","total_profiled":1310},"omim":[{"mim_id":"617438","title":"CHROMOBOX 6; CBX6","url":"https://www.omim.org/entry/617438"},{"mim_id":"608457","title":"CHROMOBOX 7; CBX7","url":"https://www.omim.org/entry/608457"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CBX7"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"O95931","domains":[{"cath_id":"2.40.50.40","chopping":"12-71","consensus_level":"high","plddt":92.2798,"start":12,"end":71}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O95931","model_url":"https://alphafold.ebi.ac.uk/files/AF-O95931-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O95931-F1-predicted_aligned_error_v6.png","plddt_mean":66.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CBX7","jax_strain_url":"https://www.jax.org/strain/search?query=CBX7"},"sequence":{"accession":"O95931","fasta_url":"https://rest.uniprot.org/uniprotkb/O95931.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O95931/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O95931"}},"corpus_meta":[{"pmid":"20541999","id":"PMC_20541999","title":"Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a.","date":"2010","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/20541999","citation_count":1125,"is_preprint":false},{"pmid":"14647293","id":"PMC_14647293","title":"Polycomb CBX7 has a unifying role in cellular lifespan.","date":"2003","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/14647293","citation_count":264,"is_preprint":false},{"pmid":"22226354","id":"PMC_22226354","title":"MicroRNA regulation of Cbx7 mediates a switch of Polycomb orthologs during ESC differentiation.","date":"2012","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/22226354","citation_count":170,"is_preprint":false},{"pmid":"23273917","id":"PMC_23273917","title":"RYBP and Cbx7 define specific biological functions of polycomb complexes in mouse embryonic stem cells.","date":"2012","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/23273917","citation_count":168,"is_preprint":false},{"pmid":"17374722","id":"PMC_17374722","title":"Role of the chromobox protein CBX7 in lymphomagenesis.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17374722","citation_count":141,"is_preprint":false},{"pmid":"22214847","id":"PMC_22214847","title":"CBX7 is a tumor suppressor in mice and humans.","date":"2012","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/22214847","citation_count":125,"is_preprint":false},{"pmid":"15897876","id":"PMC_15897876","title":"CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15897876","citation_count":122,"is_preprint":false},{"pmid":"25660273","id":"PMC_25660273","title":"Small-molecule modulators of methyl-lysine binding for the CBX7 chromodomain.","date":"2015","source":"Chemistry & biology","url":"https://pubmed.ncbi.nlm.nih.gov/25660273","citation_count":97,"is_preprint":false},{"pmid":"27723458","id":"PMC_27723458","title":"Live-cell single-molecule tracking reveals co-recognition of H3K27me3 and DNA targets polycomb Cbx7-PRC1 to chromatin.","date":"2016","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/27723458","citation_count":94,"is_preprint":false},{"pmid":"29422082","id":"PMC_29422082","title":"CBX7 regulates stem cell-like properties of gastric cancer cells via p16 and AKT-NF-κB-miR-21 pathways.","date":"2018","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29422082","citation_count":93,"is_preprint":false},{"pmid":"24625057","id":"PMC_24625057","title":"Chromodomain antagonists that target the polycomb-group methyllysine reader protein chromobox homolog 7 (CBX7).","date":"2014","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24625057","citation_count":79,"is_preprint":false},{"pmid":"21779448","id":"PMC_21779448","title":"Identification of a New Pathway for Tumor Progression: MicroRNA-181b Up-Regulation and CBX7 Down-Regulation by HMGA1 Protein.","date":"2010","source":"Genes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21779448","citation_count":69,"is_preprint":false},{"pmid":"25351982","id":"PMC_25351982","title":"CBX7 inhibits breast tumorigenicity through DKK-1-mediated suppression of the Wnt/β-catenin pathway.","date":"2014","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/25351982","citation_count":62,"is_preprint":false},{"pmid":"19602592","id":"PMC_19602592","title":"Polycomb CBX7 promotes initiation of heritable repression of genes frequently silenced with cancer-specific DNA hypermethylation.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19602592","citation_count":62,"is_preprint":false},{"pmid":"20723236","id":"PMC_20723236","title":"Oncogenic role of the chromobox protein CBX7 in gastric cancer.","date":"2010","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/20723236","citation_count":55,"is_preprint":false},{"pmid":"27326334","id":"PMC_27326334","title":"Structure-Guided Discovery of Selective Antagonists for the Chromodomain of Polycomb Repressive Protein CBX7.","date":"2016","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/27326334","citation_count":54,"is_preprint":false},{"pmid":"26175930","id":"PMC_26175930","title":"Polycomb protein family member CBX7 plays a critical role in cancer progression.","date":"2015","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/26175930","citation_count":53,"is_preprint":false},{"pmid":"31422906","id":"PMC_31422906","title":"Discovery and Characterization of a Cellular Potent Positive Allosteric Modulator of the Polycomb Repressive Complex 1 Chromodomain, CBX7.","date":"2019","source":"Cell chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/31422906","citation_count":48,"is_preprint":false},{"pmid":"34035231","id":"PMC_34035231","title":"CBX7 suppresses urinary bladder cancer progression via modulating AKR1B10-ERK signaling.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34035231","citation_count":44,"is_preprint":false},{"pmid":"28030829","id":"PMC_28030829","title":"CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28030829","citation_count":42,"is_preprint":false},{"pmid":"29309209","id":"PMC_29309209","title":"Robustness of In Vitro Selection Assays of DNA-Encoded Peptidomimetic Ligands to CBX7 and CBX8.","date":"2018","source":"SLAS discovery : advancing life sciences R & D","url":"https://pubmed.ncbi.nlm.nih.gov/29309209","citation_count":42,"is_preprint":false},{"pmid":"21060834","id":"PMC_21060834","title":"Polycomb CBX7 directly controls trimethylation of histone H3 at lysine 9 at the p16 locus.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21060834","citation_count":42,"is_preprint":false},{"pmid":"27449098","id":"PMC_27449098","title":"Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27449098","citation_count":36,"is_preprint":false},{"pmid":"30584339","id":"PMC_30584339","title":"miRNA-19 promotes non-small-cell lung cancer cell proliferation via inhibiting CBX7 expression.","date":"2018","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30584339","citation_count":36,"is_preprint":false},{"pmid":"33400401","id":"PMC_33400401","title":"Multiomics integrative analysis reveals antagonistic roles of CBX2 and CBX7 in metabolic reprogramming of breast cancer.","date":"2021","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33400401","citation_count":35,"is_preprint":false},{"pmid":"28388562","id":"PMC_28388562","title":"CBX7 negatively regulates migration and invasion in glioma via Wnt/β-catenin pathway inactivation.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28388562","citation_count":33,"is_preprint":false},{"pmid":"32205869","id":"PMC_32205869","title":"CBX7 binds the E-box to inhibit TWIST-1 function and inhibit tumorigenicity and metastatic potential.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32205869","citation_count":33,"is_preprint":false},{"pmid":"27291091","id":"PMC_27291091","title":"Cbx7 is epigenetically silenced in glioblastoma and inhibits cell migration by targeting YAP/TAZ-dependent transcription.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27291091","citation_count":32,"is_preprint":false},{"pmid":"25596753","id":"PMC_25596753","title":"Up-regulation of miR-9 target CBX7 to regulate invasion ability of bladder transitional cell carcinoma.","date":"2015","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/25596753","citation_count":32,"is_preprint":false},{"pmid":"30759399","id":"PMC_30759399","title":"CBX7 Induces Self-Renewal of Human Normal and Malignant Hematopoietic Stem and Progenitor Cells by Canonical and Non-canonical Interactions.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30759399","citation_count":32,"is_preprint":false},{"pmid":"24865347","id":"PMC_24865347","title":"CBX7 modulates the expression of genes critical for cancer progression.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24865347","citation_count":29,"is_preprint":false},{"pmid":"22544325","id":"PMC_22544325","title":"Tumor suppressor activity of CBX7 in lung carcinogenesis.","date":"2012","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/22544325","citation_count":29,"is_preprint":false},{"pmid":"32201260","id":"PMC_32201260","title":"The Crosstalk between lncRNA-SNHG7/miRNA-181/cbx7 Modulates Malignant Character in Lung Adenocarcinoma.","date":"2020","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32201260","citation_count":28,"is_preprint":false},{"pmid":"24100156","id":"PMC_24100156","title":"Synthetic trimethyllysine receptors that bind histone 3, trimethyllysine 27 (H3K27me3) and disrupt its interaction with the epigenetic reader protein CBX7.","date":"2013","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24100156","citation_count":28,"is_preprint":false},{"pmid":"31709304","id":"PMC_31709304","title":"CBX7 Inhibits Cell Growth and Motility and Induces Apoptosis in Cervical Cancer Cells.","date":"2019","source":"Molecular therapy oncolytics","url":"https://pubmed.ncbi.nlm.nih.gov/31709304","citation_count":28,"is_preprint":false},{"pmid":"26216446","id":"PMC_26216446","title":"Restoration of CBX7 expression increases the susceptibility of human lung carcinoma cells to irinotecan treatment.","date":"2015","source":"Naunyn-Schmiedeberg's archives of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26216446","citation_count":24,"is_preprint":false},{"pmid":"35693076","id":"PMC_35693076","title":"Circ_0006790 carried by bone marrow mesenchymal stem cell-derived exosomes regulates S100A11 DNA methylation through binding to CBX7 in pancreatic ductal adenocarcinoma.","date":"2022","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35693076","citation_count":23,"is_preprint":false},{"pmid":"28259135","id":"PMC_28259135","title":"miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene.","date":"2017","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28259135","citation_count":23,"is_preprint":false},{"pmid":"28123848","id":"PMC_28123848","title":"The malignancy of miR-18a in human glioblastoma via directly targeting CBX7.","date":"2017","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28123848","citation_count":22,"is_preprint":false},{"pmid":"29073373","id":"PMC_29073373","title":"Denaturing CLIP, dCLIP, Pipeline Identifies Discrete RNA Footprints on Chromatin-Associated Proteins and Reveals that CBX7 Targets 3' UTRs to Regulate mRNA Expression.","date":"2017","source":"Cell systems","url":"https://pubmed.ncbi.nlm.nih.gov/29073373","citation_count":22,"is_preprint":false},{"pmid":"35342353","id":"PMC_35342353","title":"The RNF26/CBX7 axis modulates the TNF pathway to promote cell proliferation and regulate sensitivity to TKIs in ccRCC.","date":"2022","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35342353","citation_count":21,"is_preprint":false},{"pmid":"26416703","id":"PMC_26416703","title":"CBX7 and miR-9 are part of an autoregulatory loop controlling p16(INK) (4a).","date":"2015","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/26416703","citation_count":20,"is_preprint":false},{"pmid":"32390514","id":"PMC_32390514","title":"CBX7 suppression prevents ischemia-reperfusion injury-induced endoplasmic reticulum stress through the Nrf-2/HO-1 pathway.","date":"2020","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32390514","citation_count":19,"is_preprint":false},{"pmid":"29386090","id":"PMC_29386090","title":"[ARTICLE WITHDRAWN] MicroRNA-18a Targets IRF2 and CBX7 to Promote Cell Proliferation in Hepatocellular Carcinoma.","date":"2018","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/29386090","citation_count":19,"is_preprint":false},{"pmid":"37158107","id":"PMC_37158107","title":"Polycomb Group Protein CBX7 Represses Cardiomyocyte Proliferation Through Modulation of the TARDBP/RBM38 Axis.","date":"2023","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/37158107","citation_count":18,"is_preprint":false},{"pmid":"34977026","id":"PMC_34977026","title":"PDE4B Induces Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Is Transcriptionally Suppressed by CBX7.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34977026","citation_count":18,"is_preprint":false},{"pmid":"34659360","id":"PMC_34659360","title":"CBX7 is Dualistic in Cancer Progression Based on its Function and Molecular Interactions.","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34659360","citation_count":17,"is_preprint":false},{"pmid":"25881303","id":"PMC_25881303","title":"Critical evaluation of Cbx7 downregulation in primary colon carcinomas and its clinical significance in Chinese patients.","date":"2015","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25881303","citation_count":17,"is_preprint":false},{"pmid":"31211140","id":"PMC_31211140","title":"Single Nucleotide Polymorphisms of CBX4 and CBX7 Decrease the Risk of Hepatocellular Carcinoma.","date":"2019","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/31211140","citation_count":17,"is_preprint":false},{"pmid":"29717132","id":"PMC_29717132","title":"Potential role of CBX7 in regulating pluripotency of adult human pluripotent-like olfactory stem cells in stroke model.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29717132","citation_count":17,"is_preprint":false},{"pmid":"29459770","id":"PMC_29459770","title":"Polycomb protein family member CBX7 regulates intrinsic axon growth and regeneration.","date":"2018","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/29459770","citation_count":16,"is_preprint":false},{"pmid":"32621571","id":"PMC_32621571","title":"Resveratrol inhibits oral squamous cell carcinoma cells proliferation while promoting apoptosis through inhibition of CBX7 protein.","date":"2020","source":"Environmental toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/32621571","citation_count":15,"is_preprint":false},{"pmid":"25434821","id":"PMC_25434821","title":"Tracing dynamics and clonal heterogeneity of Cbx7-induced leukemic stem cells by cellular barcoding.","date":"2014","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/25434821","citation_count":15,"is_preprint":false},{"pmid":"32273717","id":"PMC_32273717","title":"lncRNA NEAT1 Facilitates Cell Proliferation, Invasion and Migration by Regulating CBX7 and RTCB in Breast Cancer.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32273717","citation_count":15,"is_preprint":false},{"pmid":"30023485","id":"PMC_30023485","title":"Structure-Activity Relationships of Cbx7 Inhibitors, Including Selectivity Studies against Other Cbx Proteins.","date":"2016","source":"ACS omega","url":"https://pubmed.ncbi.nlm.nih.gov/30023485","citation_count":14,"is_preprint":false},{"pmid":"38037081","id":"PMC_38037081","title":"Adipose-derived exosomal miR-421 targets CBX7 and promotes metastatic potential in ovarian cancer cells.","date":"2023","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/38037081","citation_count":13,"is_preprint":false},{"pmid":"33245100","id":"PMC_33245100","title":"Regulation of circGOLPH3 and its binding protein CBX7 on the proliferation and apoptosis of prostate cancer cells.","date":"2020","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/33245100","citation_count":13,"is_preprint":false},{"pmid":"36396821","id":"PMC_36396821","title":"Downregulation of CBX7 induced by EZH2 upregulates FGFR3 expression to reduce sensitivity to cisplatin in bladder cancer.","date":"2022","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36396821","citation_count":12,"is_preprint":false},{"pmid":"27271093","id":"PMC_27271093","title":"CBX7 deficiency plays a positive role in dentin and alveolar bone development.","date":"2016","source":"Journal of molecular histology","url":"https://pubmed.ncbi.nlm.nih.gov/27271093","citation_count":12,"is_preprint":false},{"pmid":"24194518","id":"PMC_24194518","title":"Mitogen-activated protein kinase signaling mediates phosphorylation of polycomb ortholog Cbx7.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24194518","citation_count":11,"is_preprint":false},{"pmid":"35867177","id":"PMC_35867177","title":"Liver-specific deletion of miR-181ab1 reduces liver tumour progression via upregulation of CBX7.","date":"2022","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/35867177","citation_count":11,"is_preprint":false},{"pmid":"36222130","id":"PMC_36222130","title":"Knockdown of CBX7 inhibits ferroptosis in rats with cerebral ischemia and improves cognitive dysfunction by activating the Nrf2/HO-1 pathway.","date":"2022","source":"Journal of biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/36222130","citation_count":11,"is_preprint":false},{"pmid":"35843065","id":"PMC_35843065","title":"CBX7 regulates metastasis of basal-like breast cancer through Twist1/EphA2 pathway.","date":"2022","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35843065","citation_count":10,"is_preprint":false},{"pmid":"38413558","id":"PMC_38413558","title":"IGF-1-mediated FOXC1 overexpression induces stem-like properties through upregulating CBX7 and IGF-1R in esophageal squamous cell carcinoma.","date":"2024","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/38413558","citation_count":10,"is_preprint":false},{"pmid":"31630421","id":"PMC_31630421","title":"Mechanisms of ischaemic neural progenitor proliferation: a regulatory role of the HIF-1α-CBX7 pathway.","date":"2019","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/31630421","citation_count":10,"is_preprint":false},{"pmid":"18686603","id":"PMC_18686603","title":"[MiR-9 regulates the expression of CBX7 in human glioma].","date":"2008","source":"Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae","url":"https://pubmed.ncbi.nlm.nih.gov/18686603","citation_count":10,"is_preprint":false},{"pmid":"32495862","id":"PMC_32495862","title":"MicroRNA-18a suppresses ovarian carcinoma progression by targeting CBX7 and regulating ERK/MAPK signaling pathway and epithelial-to-mesenchymal transition.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32495862","citation_count":10,"is_preprint":false},{"pmid":"38157079","id":"PMC_38157079","title":"LncRNA RNA ROR Aggravates Hypoxia/Reoxygenation-Induced Cardiomyocyte Ferroptosis by Targeting miR-769-5p/CBX7 Axis.","date":"2023","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38157079","citation_count":9,"is_preprint":false},{"pmid":"32415167","id":"PMC_32415167","title":"Mammalian CBX7 isoforms p36 and p22 exhibit differential responses to serum, varying functions for proliferation, and distinct subcellular localization.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32415167","citation_count":9,"is_preprint":false},{"pmid":"30238429","id":"PMC_30238429","title":"Effect of CBX7 deficiency on the socket healing after tooth extractions.","date":"2018","source":"Journal of bone and mineral metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30238429","citation_count":8,"is_preprint":false},{"pmid":"39179168","id":"PMC_39179168","title":"CBX7 promotes choroidal neovascularization by activating the HIF-1α/VEGF pathway in choroidal vascular endothelial cells.","date":"2024","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/39179168","citation_count":7,"is_preprint":false},{"pmid":"34281957","id":"PMC_34281957","title":"Expression and correlation analysis of Skp2 and CBX7 in cervical cancer.","date":"2021","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34281957","citation_count":7,"is_preprint":false},{"pmid":"31254321","id":"PMC_31254321","title":"Rational Adaptation of L3MBTL1 Inhibitors to Create Small-Molecule Cbx7 Antagonists.","date":"2019","source":"ChemMedChem","url":"https://pubmed.ncbi.nlm.nih.gov/31254321","citation_count":7,"is_preprint":false},{"pmid":"29723807","id":"PMC_29723807","title":"The molecular selectivity of UNC3866 inhibitor for Polycomb CBX7 protein from molecular dynamics simulation.","date":"2018","source":"Computational biology and chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29723807","citation_count":6,"is_preprint":false},{"pmid":"25759796","id":"PMC_25759796","title":"CBX7 Expression in Oncocytic Thyroid Neoplastic Lesions (Hürthle Cell Adenomas and Carcinomas).","date":"2014","source":"European thyroid journal","url":"https://pubmed.ncbi.nlm.nih.gov/25759796","citation_count":6,"is_preprint":false},{"pmid":"39456039","id":"PMC_39456039","title":"RNF2 promotes chondrosarcoma progression by regulating ubiquitination and degradation of CBX7.","date":"2024","source":"Cancer & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/39456039","citation_count":5,"is_preprint":false},{"pmid":"35526483","id":"PMC_35526483","title":"CBX7 represses the POU2F2 to inhibit the PD-L1 expression and regulate the immune response in bladder cancer.","date":"2022","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/35526483","citation_count":5,"is_preprint":false},{"pmid":"37553450","id":"PMC_37553450","title":"Subcellular expression pattern and clinical significance of CBX2 and CBX7 in breast cancer subtypes.","date":"2023","source":"Medical molecular morphology","url":"https://pubmed.ncbi.nlm.nih.gov/37553450","citation_count":5,"is_preprint":false},{"pmid":"28966944","id":"PMC_28966944","title":"Producing GST-Cbx7 Fusion Proteins from Escherichia coli.","date":"2017","source":"Bio-protocol","url":"https://pubmed.ncbi.nlm.nih.gov/28966944","citation_count":5,"is_preprint":false},{"pmid":"37791390","id":"PMC_37791390","title":"CBX7 reprograms metabolic flux to protect against meningioma progression by modulating the USP44/c-MYC/LDHA axis.","date":"2024","source":"Journal of molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/37791390","citation_count":5,"is_preprint":false},{"pmid":"28220557","id":"PMC_28220557","title":"Aza-amino acid scanning of chromobox homolog 7 (CBX7) ligands.","date":"2017","source":"Journal of peptide science : an official publication of the European Peptide Society","url":"https://pubmed.ncbi.nlm.nih.gov/28220557","citation_count":5,"is_preprint":false},{"pmid":"38112798","id":"PMC_38112798","title":"Decoding the interaction between miR-19a and CBX7 focusing on the implications for tumor suppression in cancer therapy.","date":"2023","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/38112798","citation_count":3,"is_preprint":false},{"pmid":"36920677","id":"PMC_36920677","title":"CBX7 Rejuvenates Late Passage Dental Pulp Stem Cells by Maintaining Stemness and Pro-angiogenic Ability.","date":"2023","source":"Tissue engineering and regenerative medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36920677","citation_count":3,"is_preprint":false},{"pmid":"38744845","id":"PMC_38744845","title":"CBX7 silencing promoted liver regeneration by interacting with BMI1 and activating the Nrf2/ARE signaling pathway.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/38744845","citation_count":3,"is_preprint":false},{"pmid":"38809351","id":"PMC_38809351","title":"Targeting the Ferroptosis and Endoplasmic Reticulum Stress Signaling Pathways by CBX7 in Myocardial Ischemia/reperfusion Injury.","date":"2024","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/38809351","citation_count":3,"is_preprint":false},{"pmid":"37753387","id":"PMC_37753387","title":"Cbx7 promotes the generation of induced pluripotent stem cells.","date":"2023","source":"Regenerative therapy","url":"https://pubmed.ncbi.nlm.nih.gov/37753387","citation_count":3,"is_preprint":false},{"pmid":"36098711","id":"PMC_36098711","title":"The expression of miR-181b, CYLD, CBX-7, BCL2, and p53 in osteosarcoma patients and correlation with clinicopathological factors.","date":"2022","source":"Chemical biology & drug design","url":"https://pubmed.ncbi.nlm.nih.gov/36098711","citation_count":2,"is_preprint":false},{"pmid":"39033888","id":"PMC_39033888","title":"A novel nanoplatform-based circCSNK1G3 affects CBX7 protein and promotes glioma cell growth.","date":"2024","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/39033888","citation_count":2,"is_preprint":false},{"pmid":"32848416","id":"PMC_32848416","title":"lncRNA NEAT1 Facilitates Cell Proliferation, Invasion and Migration by Regulating CBX7 and RTCB in Breast Cancer [Retraction].","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32848416","citation_count":2,"is_preprint":false},{"pmid":"38028179","id":"PMC_38028179","title":"CBX7 is involved in the progression of cervical cancer through the ITGβ3/TGFβ1/AKT pathway.","date":"2023","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/38028179","citation_count":1,"is_preprint":false},{"pmid":"40473309","id":"PMC_40473309","title":"Genome-wide association study reveals CBX7 as a novel susceptibility gene associated with primary spontaneous pneumothorax in the Chinese Han population.","date":"2025","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/40473309","citation_count":1,"is_preprint":false},{"pmid":"39613290","id":"PMC_39613290","title":"CBX7 inhibitors affect H3K9 methyltransferase-regulated gene repression in leukemic cells.","date":"2024","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/39613290","citation_count":1,"is_preprint":false},{"pmid":"40998236","id":"PMC_40998236","title":"Chromobox protein homolog 7 (CBX7) deficiency inhibits osteoblast ferroptosis by activating the Nrf2 function in type 2 diabetic osteoporosis.","date":"2025","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/40998236","citation_count":1,"is_preprint":false},{"pmid":"41117088","id":"PMC_41117088","title":"Engineered Multifunctional Hydrogel Delivering Novel CBX7 Inhibitor Modulates Cuproptosis Via Liquid-Liquid Phase Separation to Restore Cardiac Function in Aged Myocardial Infarction.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/41117088","citation_count":1,"is_preprint":false},{"pmid":"41250171","id":"PMC_41250171","title":"CBX7 regulates chemotherapy-induced senescence-like growth arrest in multiple myeloma via the ERK/STAT3/PIM1 axis.","date":"2025","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41250171","citation_count":1,"is_preprint":false},{"pmid":"40387566","id":"PMC_40387566","title":"DNMT1-Induced Downregulation of CBX7 Inhibits ERK Phosphorylation and Promotes Pancreatic Ductal Adenocarcinoma Progression.","date":"2025","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/40387566","citation_count":0,"is_preprint":false},{"pmid":"37986971","id":"PMC_37986971","title":"Adipose-derived exosomal miR-421 targets CBX7 and promotes metastatic potential in ovarian cancer cells.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/37986971","citation_count":0,"is_preprint":false},{"pmid":"41582043","id":"PMC_41582043","title":"Histone H3.3 phosphorylation facilitates H3K9me3-heterochromatin formation during retrotransposon silencing and X-chromosome inactivation via H3.3K27me3-CBX7-KAP1 axis.","date":"2026","source":"Science bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/41582043","citation_count":0,"is_preprint":false},{"pmid":"40552137","id":"PMC_40552137","title":"Pharmacological targeting of CBX7 alters the epigenetic landscape and induces differentiation of leukemic cells.","date":"2024","source":"Blood neoplasia","url":"https://pubmed.ncbi.nlm.nih.gov/40552137","citation_count":0,"is_preprint":false},{"pmid":"41686891","id":"PMC_41686891","title":"CBX7 functions as a methylation-dependent inducer of gene transcription and regulator of cytosolic signaling in lymphoid cells.","date":"2026","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/41686891","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48796,"output_tokens":8152,"usd":0.134334},"stage2":{"model":"claude-opus-4-6","input_tokens":11924,"output_tokens":5228,"usd":0.28548},"total_usd":0.419814,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2010,\n      \"finding\": \"CBX7 chromodomain binds both trimethylated histone H3K27me3 and the noncoding RNA ANRIL; both interactions are required for CBX7-mediated repression of the INK4b/ARF/INK4a locus. Structure-guided NMR analysis revealed the molecular interplay between RNA and H3K27me3 binding within the conserved chromodomain, and disruption of either interaction impairs senescence control.\",\n      \"method\": \"Co-IP, NMR structure, RNA-binding assays, chromodomain mutagenesis, ChIP, senescence assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structure-guided analysis with mutagenesis, multiple orthogonal methods in a single high-impact study\",\n      \"pmids\": [\"20541999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CBX7 is a Polycomb group protein that interacts with Ring1, localizes to nuclear Polycomb bodies, and extends cellular lifespan by repressing the Ink4a/Arf locus through the p16(Ink4a)/Rb and Arf/p53 pathways; it does not co-localize or interact functionally with Bmi1.\",\n      \"method\": \"Genetic screen, Co-IP, shRNA knockdown, immunofluorescence localization, functional lifespan and growth assays\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal interaction data, direct localization, reverse-genetics with defined phenotype; foundational study with >260 citations\",\n      \"pmids\": [\"14647293\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Cbx7 is the primary PRC1 Polycomb ortholog in mouse embryonic stem cells (ESCs); it directly represses Cbx2, Cbx4, and Cbx8, and its expression is regulated by the miR-125 and miR-181 families. Cbx7 loss induces ESC differentiation while its ectopic expression inhibits differentiation and enhances self-renewal.\",\n      \"method\": \"Gain- and loss-of-function (KD/OE), ChIP, functional miRNA screen, differentiation assays, X-chromosome inactivation assays\",\n      \"journal\": \"Cell stem cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, replicated across multiple assays; >170 citations\",\n      \"pmids\": [\"22226354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"In mouse ESCs, Cbx7 (but not RYBP) is necessary for recruitment of Ring1B to chromatin; Cbx7-containing PRC1 complexes and RYBP-containing PRC1 complexes are mutually exclusive and regulate distinct gene sets, with Cbx7-occupied genes controlling early-lineage commitment.\",\n      \"method\": \"ChIP-seq, Co-IP, siRNA knockdown, Ring1B chromatin fractionation, gene expression profiling\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, ChIP-seq, and genetic KD with defined molecular phenotype; >160 citations\",\n      \"pmids\": [\"23273917\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Cbx7 initiates T cell lymphomagenesis in mice and cooperates with c-Myc to produce B cell lymphomas; it represses the Ink4a/Arf locus and acts epistatically upstream of the Arf-p53 pathway during tumorigenesis.\",\n      \"method\": \"Transgenic mouse model (lymphoid-targeted Cbx7 expression), genetic epistasis, tumor analysis, Ink4a/Arf expression assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic epistasis with defined tumor phenotype; >140 citations\",\n      \"pmids\": [\"17374722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CBX7 acts as a tumor suppressor by binding to the CCNE1 (cyclin E) promoter in a complex with HDAC2 to negatively regulate cyclin E expression; Cbx7-knockout mice develop liver and lung adenomas and carcinomas, with upregulated cyclin E.\",\n      \"method\": \"Cbx7-KO mouse generation, ChIP, Co-IP with HDAC2, gene expression analysis in KO MEFs and tumors, in vivo/in vitro assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — KO mouse model, ChIP demonstrating direct promoter binding, co-IP identifying HDAC2 complex; >125 citations\",\n      \"pmids\": [\"22214847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The CBX7 chromodomain binds H3K27me3 through an aromatic cage; small molecules (MS37452) that occupy the methyl-lysine binding pocket competitively inhibit this interaction and derepress p16/CDKN2A in prostate cancer cells by displacing CBX7 from the INK4A/ARF locus.\",\n      \"method\": \"Crystal structures of CBX7ChD-ligand complexes, fluorescence polarization binding assays, ChIP in prostate cancer cells\",\n      \"journal\": \"Chemistry & biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures with functional cellular validation; >97 citations\",\n      \"pmids\": [\"25660273\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Live-cell single-molecule tracking revealed that Cbx7 is targeted to chromatin by co-recognition of H3K27me3 and DNA; biochemical analysis identified an AT-hook-like (ATL) motif that, together with the chromodomain, constitutes a functional DNA-binding unit. Disrupting PRC1 complex formation facilitates Cbx7 chromatin targeting.\",\n      \"method\": \"Live-cell single-molecule tracking (SMT), genetic engineering of Cbx7 mutants, biochemical DNA-binding assays, CRISPR-based H3K27me3 disruption\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — live-cell SMT combined with mutagenesis and biochemical assays; >94 citations\",\n      \"pmids\": [\"27723458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Peptidomimetic inhibitors of CBX7 targeting the H3K27me3-binding chromodomain were developed; NMR and X-ray crystal structures of ligand-chromodomain complexes revealed a structural motif unique to CBX7 among human CBX proteins, enabling ~200 nM potency with 10-fold selectivity over CBX8.\",\n      \"method\": \"Fluorescence polarization, isothermal titration calorimetry, 2D NMR, X-ray crystallography\",\n      \"journal\": \"Journal of medicinal chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure and NMR with quantitative binding characterization\",\n      \"pmids\": [\"24625057\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CBX7 associates with DNA methyltransferase (DNMT) enzymes and can initiate stable epigenetic silencing of genes frequently hypermethylated in cancer. In embryonal carcinoma cells, CBX7 promotes DNMT assembly at target gene promoters and initiates DNA hypermethylation.\",\n      \"method\": \"Co-IP (CBX7-DNMT complex), ChIP, shRNA knockdown, gene expression and methylation assays in EC cells\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP and ChIP showing DNMT recruitment, but complex formation characterized only by single-lab pulldown\",\n      \"pmids\": [\"19602592\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CBX7 directly initiates H3K9me3 formation at the p16 promoter by forming a complex with the methyltransferase SUV39H2; this interaction was demonstrated by bimolecular fluorescence complementation and co-IP, and requires an intact chromodomain and Pc-box. siRNA knockdown of Suv39h2 blocks CBX7-mediated p16 repression.\",\n      \"method\": \"Co-IP, bimolecular fluorescence complementation (BiFC), ChIP, siRNA knockdown, CBX7 chromodomain/Pc-box mutants\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — BiFC and Co-IP with genetic validation by mutagenesis and siRNA; single lab\",\n      \"pmids\": [\"21060834\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"MAPK signaling phosphorylates Cbx7 at Thr-118 (near the conserved Polycomb box); this phosphorylation, detected by a site-specific antibody and mass spectrometry, moderately enhances p16 repression and is induced upon EGF stimulation, which also triggers robust interaction of Cbx7 with other PRC1 members.\",\n      \"method\": \"Mass spectrometry, site-specific antibody, MEK inhibitor treatment, Co-IP after EGF stimulation, RAS-induced senescence assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — MS identification + site-specific antibody + functional mutagenesis + epistasis in senescence model\",\n      \"pmids\": [\"24194518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"dCLIP (denaturing CLIP) showed that CBX7 predominantly binds 3' UTRs of messenger RNAs with a median footprint of ~171-183 nucleotides. Four families of consensus RNA-binding motifs were identified; their mutation abolishes CBX7 binding in vitro. Antisense oligonucleotide (ASO) intervention paradoxically increases CBX7 binding and enhances gene expression.\",\n      \"method\": \"dCLIP-seq (UV crosslink immunoprecipitation with denaturation), bioinformatics motif analysis, in vitro binding with mutant motifs, ASO treatment\",\n      \"journal\": \"Cell systems\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genome-wide CLIP with motif mutagenesis validation in vitro; independently validated in mouse and human\",\n      \"pmids\": [\"29073373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CBX7 interacts non-canonically with H3K9 methyltransferases SETDB1, EHMT1, and EHMT2 (which contain trimethylated lysine motifs similar to H3K27me3); mass spectrometry identified these interactions, and depletion of SETDB1 in AML cells phenocopies CBX7 repression, establishing a non-canonical crosstalk pathway that controls HSPC self-renewal.\",\n      \"method\": \"Mass spectrometry interactome, Co-IP, genetic depletion (shRNA), AML cell proliferation and differentiation assays, xenotransplantation\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — MS-based interactome confirmed by Co-IP, with epistasis via SETDB1 KD phenocopying CBX7; multiple orthogonal methods\",\n      \"pmids\": [\"30759399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A positive allosteric modulator (PAM) peptidomimetic UNC4976 simultaneously antagonizes H3K27me3-specific recruitment of CBX7 to target genes while increasing non-specific binding to DNA and RNA, thereby reequilibrating PRC1 away from H3K27me3-marked regions. This reveals that CBX7 nucleic acid binding and histone binding are allosterically coupled.\",\n      \"method\": \"Quantitative cellular assay, fluorescence polarization, three orthogonal cellular assays, ChIP\",\n      \"journal\": \"Cell chemical biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple cellular assays with mechanistic interpretation; single lab\",\n      \"pmids\": [\"31422906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Structure-guided discovery identified Class A CBX7 chromodomain antagonists that inhibit methyl-lysine binding and Class B compounds (MS351) that inhibit H3K27me3 binding when CBX7 is bound to RNA. Crystal structure of CBX7ChD/MS351 reveals ligand recognition by aromatic cage residues that engage methyl-lysine. MS351 induces transcriptional derepression of p16(INK4a) in ESCs and prostate cancer cells.\",\n      \"method\": \"Crystal structure of CBX7ChD/MS351 complex, fluorescence polarization, ChIP, gene expression assays\",\n      \"journal\": \"ACS medicinal chemistry letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional cellular validation by ChIP and gene expression\",\n      \"pmids\": [\"27326334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CBX7 inhibits breast tumorigenicity by increasing DKK-1 transcription through cooperation with p300 acetyltransferase, enhancing histone acetylation at the DKK-1 promoter, thereby suppressing Wnt/β-catenin/TCF signaling. Pharmacological DKK-1 inhibition reverses CBX7-mediated Wnt suppression.\",\n      \"method\": \"ChIP (histone acetylation at DKK-1 promoter), Co-IP (CBX7-p300), luciferase reporter assay, shRNA KD, pharmacological inhibitor rescue, in vivo tumor initiation assay\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and Co-IP with functional rescue; single lab\",\n      \"pmids\": [\"25351982\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CBX7 binds the E-box and prevents TWIST-1 from binding its transcriptional targets in secondary epithelial ovarian cancer cells; deletion of CBX7 is sufficient to reactivate TWIST-1-induced transcription and restore mesenchymal transformation and tumorigenicity.\",\n      \"method\": \"CBX7 deletion (CRISPR/genetic), E-box binding assay, in vitro and in vivo tumorigenicity assays, EMT marker analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined molecular mechanism (E-box competition) with in vivo phenotype; single lab\",\n      \"pmids\": [\"32205869\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CBX7 represses YAP/TAZ-dependent transcription in glioma cells, leading to downregulation of CTGF and reduced phospho-JNK; CBX7 overexpression inhibits cell migration, and migration inhibition is reversed by exogenous CTGF or constitutively active JNK. Cbx7 promoter is hypermethylated in GBM.\",\n      \"method\": \"GSEA of CBX7-regulated genes, Western blot (YAP/TAZ, CTGF, pJNK), exogenous CTGF rescue, constitutively active JNK rescue, bisulfite sequencing\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — pathway placement by epistasis with rescue experiments; single lab\",\n      \"pmids\": [\"27291091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CBX7 suppresses AKR1B10 transcription in a PRC1-dependent manner in bladder cancer cells; loss of CBX7 leads to AKR1B10 upregulation that activates ERK signaling. This was established by RNA-seq and ChIP assays identifying AKR1B10 as a direct downstream target.\",\n      \"method\": \"RNA-seq, ChIP, siRNA knockdown, small molecule inhibitor (oleanolic acid), in vivo tumor model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP confirming direct targeting, RNA-seq, and functional rescue; single lab\",\n      \"pmids\": [\"34035231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CBX7 interacts with TARDBP (TDP-43) and positively regulates its downstream target RBM38 in a TARDBP-dependent manner; this axis mediates CBX7-directed cell cycle exit of postnatal cardiomyocytes. Genetic inactivation of Cbx7 in cardiomyocytes increased proliferation, impeded cardiac maturation, and promoted heart regeneration after injury.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry, conditional cardiac KO mice (Tnnt2-Cre and Myh6-MCM), adenoviral OE, neonatal apical resection and adult MI models, proliferation marker immunostaining\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — MS-identified interaction confirmed by Co-IP, conditional KO with multiple cardiac phenotypes, epistasis via RBM38 OE rescue\",\n      \"pmids\": [\"37158107\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Two CBX7 isoforms (p36 and p22) have distinct subcellular localizations and opposing roles: p36CBX7 localizes to the nucleus and is expressed in proliferating cells, whereas p22CBX7 localizes to the cytoplasm, is induced by serum starvation, and inhibits cell proliferation.\",\n      \"method\": \"Subcellular fractionation, immunofluorescence, serum starvation experiments, proliferation assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct localization by fractionation and imaging, with functional consequence; single lab\",\n      \"pmids\": [\"32415167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CBX7 regulates axon growth and regeneration in neurons; knockdown of CBX7 in embryonic cortical neurons or adult DRG neurons enhances axon growth ability. GATA4 and SOX11 are functional downstream transcriptional targets of CBX7 in controlling axon regeneration; knockdown of GATA4 or SOX11 inhibits CBX7-knockdown-induced axon regeneration.\",\n      \"method\": \"CBX7 shRNA KD in primary neurons, DRG axon regeneration assays, genetic epistasis (GATA4/SOX11 KD rescue)\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with defined downstream targets and functional axon phenotype; single lab\",\n      \"pmids\": [\"29459770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"RNF26 acts as an E3 ubiquitin ligase that promotes ubiquitination and proteasomal degradation of CBX7 protein (without affecting CBX7 mRNA), thereby activating the TNF/ETS1 signaling pathway to promote ccRCC growth.\",\n      \"method\": \"Co-IP, ubiquitination assay, cycloheximide chase (protein stability), shRNA/OE, xenograft mouse model\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP, ubiquitination assay, and stability assay identifying RNF26 as E3 ligase; single lab\",\n      \"pmids\": [\"35342353\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"EZH2 represses CBX7 expression by increasing H3K27me3 at the CBX7 locus in bladder cancer cells; CBX7 in turn directly downregulates FGFR3 expression (confirmed by ChIP) and sensitizes bladder cancer cells to cisplatin by inactivating the PI3K/AKT signaling pathway.\",\n      \"method\": \"ChIP-qPCR (H3K27me3 at CBX7 locus; CBX7 binding at FGFR3 promoter), Western blot, RT-qPCR, CCK-8, xenograft model\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP confirming direct regulation in both directions; single lab\",\n      \"pmids\": [\"36396821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"RNF2 promotes ubiquitination and proteasomal degradation of CBX7 protein (without affecting CBX7 mRNA); knockdown of RNF2 upregulates CBX7 and reduces chondrosarcoma cell proliferation, migration, and angiogenesis, effects reversed by CBX7 knockdown.\",\n      \"method\": \"Co-IP, ubiquitination assay, cycloheximide chase, siRNA/OE, xenograft mouse model\",\n      \"journal\": \"Cancer & metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ubiquitination and stability assays with in vivo validation; single lab\",\n      \"pmids\": [\"39456039\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HIF-1α transcriptionally activates CBX7 expression during hypoxia/ischemia, and this HIF-1α-CBX7 cascade modulates neural progenitor cell (NPC) proliferation; CBX7-knockout mice generated by CRISPR/Cas9 show significantly reduced NPC numbers.\",\n      \"method\": \"ChIP (HIF-1α at CBX7 promoter), CRISPR/Cas9 KO mice, NPC proliferation assays, hypoxia model\",\n      \"journal\": \"Neuropathology and applied neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP identifying direct transcriptional regulation, CRISPR KO phenotype; single lab\",\n      \"pmids\": [\"31630421\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CBX7 promotes meningioma progression control by transcriptionally repressing USP44, a deubiquitinase for c-MYC; loss of CBX7 leads to USP44-mediated c-MYC stabilization, increased LDHA transactivation, and enhanced glycolysis. Restoration of CBX7 triggers a metabolic shift from glycolysis to oxidative phosphorylation.\",\n      \"method\": \"iTRAQ proteomics, ChIP, luciferase reporter assay, siRNA/OE, subcutaneous and orthotopic xenograft models\",\n      \"journal\": \"Journal of molecular cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — proteomics plus ChIP and reporter assay identifying USP44/c-MYC/LDHA pathway; single lab\",\n      \"pmids\": [\"37791390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"CBX7 preferentially binds Ser31-phosphorylated H3.3K27me3 nucleosomes and recruits KAP1, which engages histone lysine 9 methyltransferase to establish H3K9me3-associated heterochromatin. Disrupting the H3.3-CBX7 interaction significantly impairs H3K9me3 and activates retrotransposons; the same axis is required for H3K9me2/3 accumulation at the inactive X during X-chromosome inactivation.\",\n      \"method\": \"Biochemical nucleosome binding assays, Co-IP (CBX7-KAP1), ChIP-seq (H3K9me3), retrotransposon activation assays, X-inactivation analysis with H3.3-CBX7 interaction-blocking mutations\",\n      \"journal\": \"Science bulletin\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including biochemical reconstitution, Co-IP, ChIP-seq, and genetic disruption with defined mechanistic readouts\",\n      \"pmids\": [\"41582043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"CBX7 forms a methylation-dependent transcriptional activation complex at cytokine gene promoters (unexpectedly inducing transcription) and also translocates to the cytosol where it forms a methylation-dependent signaling complex with c-Raf, MEK1/2, and CK2-α to generate sustained ERK1/2 signaling in lymphoid cells; both activities are absent in epithelial cells.\",\n      \"method\": \"Co-IP (CBX7-c-Raf, MEK1/2, CK2-α), ChIP (CBX7 at cytokine promoters), RNA-seq, genetic KO and pharmacological inhibition in mouse and human lymphoid cells, allergic asthma mouse models\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — Co-IP, ChIP, RNA-seq, and in vivo genetic/pharmacological validation across multiple model systems\",\n      \"pmids\": [\"41686891\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In aged hearts, CBX7 forms liquid-liquid phase separation (LLPS) with ATP7A, trapping ATP7A intracellularly and reducing copper efflux, thereby triggering cuproptosis; a small-molecule inhibitor (δ-Amyrenone) that disrupts CBX7-ATP7A LLPS restores ATP7A trafficking and improves cardiac function.\",\n      \"method\": \"LLPS assay, protein interaction assay (CBX7-ATP7A), single-cell RNA-seq, high-throughput screening, in vivo mouse and minipig MI models\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — LLPS and protein interaction data with in vivo validation; novel mechanism, single lab\",\n      \"pmids\": [\"41117088\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Exosomal circ_0006790 facilitates nuclear translocation of CBX7; nuclear CBX7 then recruits DNA methyltransferases to the S100A11 promoter to increase S100A11 DNA methylation and suppress its transcription, thereby inhibiting PDAC immune escape.\",\n      \"method\": \"Exosome treatment, nuclear fractionation, ChIP (DNMT recruitment to S100A11 promoter), siRNA KD of CBX7, rescue with S100A11 OE\",\n      \"journal\": \"American journal of cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — ChIP showing DNMT recruitment, fractionation, and functional rescue; single lab\",\n      \"pmids\": [\"35693076\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"DNMT1 methylates the CBX7 promoter to suppress CBX7 expression in PDAC; silencing DNMT1 upregulates CBX7, which reduces ERK phosphorylation and suppresses tumor progression. ChIP and dual-luciferase assays confirmed direct DNMT1 binding and methylation of the CBX7 promoter.\",\n      \"method\": \"ChIP-qPCR (DNMT1 at CBX7 promoter), dual-luciferase reporter assay, siRNA knockdown, Western blot, CCK-8, wound healing, transwell assays\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and reporter assay confirming direct regulation; single lab\",\n      \"pmids\": [\"40387566\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CBX7 inhibition by small molecules abolishes CBX7 interaction with H3K9 methyltransferases EHMT1/2 and SETDB1, reduces H3K9 methylation, reactivates target gene expression, and has additive effects with EHMT1/2 or SETDB1 inhibitors on reducing leukemic cell growth and inducing differentiation.\",\n      \"method\": \"Co-IP (CBX7-EHMT1/2-SETDB1), pharmacological CBX7 inhibition, H3K9 methylation ChIP, gene expression assays, cell proliferation and differentiation assays\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP and ChIP with pharmacological intervention; single lab\",\n      \"pmids\": [\"39613290\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CBX7 is a PRC1 Polycomb group protein whose N-terminal chromodomain binds H3K27me3 (and, co-operatively, DNA via an AT-hook-like motif and noncoding RNA such as ANRIL) to repress target loci including INK4a/ARF; it recruits Ring1B and forms complexes with HDAC2, DNMTs, SUV39H2, and non-canonically with H3K9 methyltransferases SETDB1/EHMT1/EHMT2; its activity is modulated by MAPK-mediated phosphorylation (Thr-118), ubiquitin-mediated degradation by E3 ligases RNF2 and RNF26, and by HIF-1α-driven transcription; cell-type-specifically it can also act as a transcriptional activator and cytosolic ERK signaling scaffold in lymphoid cells, and in cardiomyocytes it interacts with TARDBP to regulate RBM38-dependent cell cycle exit.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CBX7 is a Polycomb Repressive Complex 1 (PRC1) subunit that functions as a multivalent chromatin reader integrating histone, DNA, and RNA recognition to enforce transcriptional silencing at developmental and tumor-suppressor loci, while also exhibiting cell-type-specific roles as a transcriptional activator and cytoplasmic signaling scaffold. Its N-terminal chromodomain recognizes H3K27me3 (preferentially on Ser31-phosphorylated H3.3 nucleosomes) through an aromatic cage, and an adjacent AT-hook-like motif cooperatively binds DNA; the chromodomain also engages noncoding RNA (ANRIL) and mRNA 3′ UTRs, with nucleic-acid and histone binding allosterically coupled [PMID:20541999, PMID:27723458, PMID:29073373, PMID:41582043]. CBX7 recruits Ring1B to chromatin in embryonic stem cells to maintain pluripotency and repress early-lineage genes, while at other loci it assembles repressive complexes containing HDAC2, DNMTs, SUV39H2, or the H3K9 methyltransferases SETDB1/EHMT1/EHMT2 to silence targets including INK4a/ARF, CCNE1, and FGFR3 [PMID:23273917, PMID:22214847, PMID:19602592, PMID:21060834, PMID:30759399]. CBX7 protein stability is regulated by ubiquitin-dependent proteasomal degradation mediated by E3 ligases RNF26 and RNF2, and its activity is modulated by MAPK-mediated Thr-118 phosphorylation; in lymphoid cells, CBX7 unexpectedly translocates to the cytosol to form a methylation-dependent signaling complex with c-Raf, MEK1/2, and CK2-α that sustains ERK signaling, while in cardiomyocytes it interacts with TARDBP to regulate RBM38-dependent cell-cycle exit [PMID:35342353, PMID:39456039, PMID:24194518, PMID:41686891, PMID:37158107].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Establishing CBX7 as a Polycomb group protein that extends replicative lifespan by repressing Ink4a/Arf resolved the question of which PcG protein directly silences this senescence-controlling locus independently of Bmi1.\",\n      \"evidence\": \"Co-IP with Ring1, immunofluorescence to Polycomb bodies, shRNA knockdown with growth/lifespan assays in human fibroblasts\",\n      \"pmids\": [\"14647293\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide targets beyond Ink4a/Arf not identified\", \"Mechanism of chromatin recruitment not resolved\", \"How CBX7 and Bmi1 complexes partition was unclear\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrating that Cbx7 overexpression initiates T-cell lymphoma and cooperates with c-Myc in B-cell lymphoma established CBX7 as an oncogene acting epistatically upstream of Arf-p53, resolving whether its Ink4a/Arf repression was tumorigenic in vivo.\",\n      \"evidence\": \"Lymphoid-targeted Cbx7 transgenic mice, genetic epistasis with Ink4a/Arf deletion and p53 pathway\",\n      \"pmids\": [\"17374722\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CBX7 has tumor-suppressive roles in other tissues was unknown\", \"Mechanism of tissue-specific oncogenicity unclear\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identifying CBX7 association with DNA methyltransferases showed that PRC1 can initiate stable DNA hypermethylation at target promoters, linking Polycomb silencing to permanent epigenetic memory.\",\n      \"evidence\": \"Co-IP of CBX7-DNMT complexes, ChIP and methylation analysis in embryonal carcinoma cells\",\n      \"pmids\": [\"19602592\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"DNMT interaction characterized by single-lab pulldown only\", \"Which DNMT isoform is principally recruited was not resolved\", \"Genome-wide extent of CBX7-dependent DNA methylation unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Structural and biochemical dissection of the CBX7 chromodomain revealed dual recognition of H3K27me3 and ANRIL ncRNA, answering how CBX7 achieves locus-specific targeting at INK4a/ARF through combinatorial chromatin and RNA readout.\",\n      \"evidence\": \"NMR structure of chromodomain, RNA-binding assays, chromodomain mutagenesis, ChIP and senescence assays\",\n      \"pmids\": [\"20541999\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which other ncRNAs contribute to CBX7 targeting was unknown\", \"Relative contributions of RNA vs. histone binding to genome-wide occupancy not quantified\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Discovery that CBX7 recruits SUV39H2 to deposit H3K9me3 at the p16 promoter revealed a PRC1-H3K9 methylation crosstalk mechanism, expanding the epigenetic toolkit downstream of CBX7 beyond canonical PRC1 activities.\",\n      \"evidence\": \"BiFC, Co-IP, ChIP, and siRNA knockdown of Suv39h2 in human cells\",\n      \"pmids\": [\"21060834\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab observation without independent replication\", \"Whether SUV39H2 interaction is direct or mediated by other PRC1 subunits unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Three contemporaneous studies established Cbx7 as the dominant PRC1 chromodomain subunit in ESCs—required for Ring1B chromatin recruitment, self-renewal maintenance, and repression of lineage-commitment genes and alternative Cbx paralogs—resolving how PRC1 composition is specified in pluripotent cells.\",\n      \"evidence\": \"ChIP-seq, Co-IP, siRNA/overexpression, miRNA screens, differentiation assays in mouse ESCs; Cbx7-KO mouse with liver/lung carcinomas and HDAC2 Co-IP\",\n      \"pmids\": [\"22226354\", \"23273917\", \"22214847\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Cbx7-to-Cbx2/4 switching is executed during differentiation was not mechanistically resolved\", \"Whether Cbx7-PRC1 and RYBP-PRC1 co-occupy any loci was untested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identification of MAPK-mediated phosphorylation at Thr-118 showed that extracellular signals dynamically modulate CBX7's PRC1 interactions and repressive activity, answering how CBX7 function is tuned by signaling inputs.\",\n      \"evidence\": \"Mass spectrometry, phospho-specific antibody, MEK inhibitor treatment, Co-IP after EGF stimulation, RAS-induced senescence assay\",\n      \"pmids\": [\"24194518\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other kinases phosphorylate CBX7 was unknown\", \"Effect of Thr-118 phosphorylation on chromatin occupancy genome-wide not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Development of peptidomimetic inhibitors with crystal structures of the CBX7 chromodomain–ligand complexes provided the first chemical tools to probe CBX7 function and revealed structural features unique to CBX7 among human CBX paralogs, enabling selective pharmacological perturbation.\",\n      \"evidence\": \"X-ray crystallography, NMR, fluorescence polarization, isothermal titration calorimetry\",\n      \"pmids\": [\"24625057\", \"25660273\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell permeability and in vivo efficacy of early compounds not established\", \"Whether inhibitors affect CBX7-RNA interactions was untested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Live-cell single-molecule tracking combined with biochemical analysis identified an AT-hook-like motif that cooperates with the chromodomain for DNA binding, establishing that CBX7 chromatin targeting requires bivalent histone-DNA co-recognition rather than H3K27me3 alone.\",\n      \"evidence\": \"Single-molecule tracking, CRISPR-mediated H3K27me3 ablation, DNA-binding assays with CBX7 mutants\",\n      \"pmids\": [\"27723458\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Sequence specificity of DNA binding not fully resolved\", \"How ATL motif integrates with RNA binding was unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Genome-wide dCLIP revealed that CBX7 binds predominantly to mRNA 3′ UTRs via defined consensus motifs, uncovering an unexpected post-transcriptional dimension of CBX7 function beyond canonical chromatin silencing.\",\n      \"evidence\": \"dCLIP-seq with motif mutagenesis validation in vitro, ASO intervention in mouse and human cells\",\n      \"pmids\": [\"29073373\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of mRNA binding on translation/stability not determined for most targets\", \"Whether mRNA binding occurs in the nucleus, cytoplasm, or both was not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Mass spectrometry-based interactomics revealed that CBX7 non-canonically engages H3K9 methyltransferases SETDB1, EHMT1, and EHMT2 via their trimethylated lysine motifs, establishing a PRC1-H3K9me crosstalk axis critical for HSPC self-renewal in AML.\",\n      \"evidence\": \"MS interactome, Co-IP, shRNA depletion phenocopying in AML cells, xenotransplantation\",\n      \"pmids\": [\"30759399\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CBX7 chromodomain directly reads methylated lysines on SETDB1/EHMTs or requires an adaptor was unclear\", \"Contribution of this axis to normal hematopoiesis vs. leukemogenesis not separated\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"A positive allosteric modulator (UNC4976) demonstrated that CBX7's histone-binding and nucleic-acid-binding activities are allosterically coupled, establishing a pharmacological principle for redistributing PRC1 away from H3K27me3-marked loci.\",\n      \"evidence\": \"Fluorescence polarization, three orthogonal cellular assays, ChIP\",\n      \"pmids\": [\"31422906\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab observation\", \"In vivo effects of allosteric modulation not tested\", \"Structural basis of allosteric coupling not resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identification of two CBX7 isoforms (p36/nuclear, p22/cytoplasmic) with opposing effects on proliferation revealed that alternative isoform usage partitions CBX7 between chromatin repression and cytoplasmic functions.\",\n      \"evidence\": \"Subcellular fractionation, immunofluorescence, serum-starvation induction, proliferation assays\",\n      \"pmids\": [\"32205869\", \"32415167\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular determinants of isoform switching unknown\", \"Cytoplasmic binding partners of p22 not identified\", \"Whether p22 retains RNA-binding capacity untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Discovery that RNF26 ubiquitinates CBX7 for proteasomal degradation identified the first E3 ligase controlling CBX7 protein turnover, explaining how CBX7 levels are post-translationally tuned in renal cell carcinoma.\",\n      \"evidence\": \"Co-IP, ubiquitination assay, cycloheximide chase, xenograft model\",\n      \"pmids\": [\"35342353\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab observation\", \"Ubiquitination site(s) on CBX7 not mapped\", \"Whether RNF26-mediated degradation operates in normal tissues unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identification of the CBX7–TARDBP–RBM38 axis in cardiomyocytes established a non-canonical mechanism by which CBX7 enforces postnatal cell-cycle exit, answering why Cbx7 loss permits cardiomyocyte proliferation and heart regeneration after injury.\",\n      \"evidence\": \"Co-IP, mass spectrometry, conditional cardiac KO mice (Tnnt2-Cre and Myh6-MCM), neonatal and adult injury models\",\n      \"pmids\": [\"37158107\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the CBX7-TARDBP interaction is chromodomain-dependent or Pc-box-dependent not resolved\", \"How this axis interfaces with canonical PRC1 silencing in cardiomyocytes unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Discovery that CBX7 undergoes liquid-liquid phase separation with ATP7A, trapping the copper transporter intracellularly and triggering cuproptosis in aged hearts, revealed a previously unrecognized biophysical mechanism linking CBX7 to copper homeostasis and cardiac aging.\",\n      \"evidence\": \"LLPS assay, protein interaction assay, scRNA-seq, high-throughput compound screening, mouse and minipig MI models\",\n      \"pmids\": [\"41117088\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab finding; LLPS mechanism not reconstituted with purified components\", \"Whether other PRC1 subunits participate in or modulate LLPS unknown\", \"Generalizability beyond cardiac tissue untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Pharmacological CBX7 inhibition abolished interactions with EHMT1/2 and SETDB1 and showed additive anti-leukemic effects with H3K9 methyltransferase inhibitors, validating the CBX7-H3K9me axis as a druggable node in AML.\",\n      \"evidence\": \"Co-IP, H3K9me ChIP, pharmacological inhibition, proliferation/differentiation assays in leukemic cells\",\n      \"pmids\": [\"39613290\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo pharmacokinetics and efficacy not reported\", \"Whether inhibitor selectivity among CBX paralogs is sufficient for therapeutic use unknown\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Biochemical and ChIP-seq studies showed CBX7 preferentially reads Ser31-phosphorylated H3.3K27me3, recruiting KAP1 and H3K9 methyltransferase to establish heterochromatin and silence retrotransposons; this axis is also required for H3K9me2/3 accumulation on the inactive X chromosome, unifying CBX7's heterochromatin roles across developmental contexts.\",\n      \"evidence\": \"Nucleosome binding assays, Co-IP (CBX7-KAP1), ChIP-seq (H3K9me3), retrotransposon reactivation, X-inactivation assays with interaction-blocking mutations\",\n      \"pmids\": [\"41582043\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which kinase deposits Ser31 phosphorylation to prime CBX7 recruitment is unknown\", \"Structural basis of Ser31-phospho recognition by CBX7 not determined\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Discovery that CBX7 functions as both a transcriptional activator and a cytoplasmic ERK-signaling scaffold in lymphoid (but not epithelial) cells fundamentally expanded the functional repertoire of PRC1 subunits, revealing cell-type-specific non-canonical roles.\",\n      \"evidence\": \"Co-IP (CBX7–c-Raf, MEK1/2, CK2-α), ChIP at cytokine promoters, RNA-seq, genetic KO and pharmacological inhibition in lymphoid cells, allergic asthma mouse models\",\n      \"pmids\": [\"41686891\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"What determines the switch from repressor to activator in lymphoid cells is unknown\", \"Whether the cytoplasmic signaling role requires the p22 isoform specifically is untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include: the structural basis for allosteric coupling between histone, DNA, and RNA binding; how cell-type-specific isoform usage and post-translational modifications partition CBX7 between canonical PRC1 silencing, transcriptional activation, cytoplasmic signaling, and phase-separation functions; and whether pharmacological targeting of CBX7 can achieve paralog selectivity sufficient for therapeutic use in cancer or cardiac regeneration.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No full-length CBX7 structure exists\", \"Isoform-specific interactomes not systematically compared\", \"In vivo efficacy of CBX7 inhibitors not demonstrated in disease models\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [0, 6, 7, 8, 14, 15, 28]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [0, 12, 14]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [7, 17]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 5, 16, 19, 27, 29]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [29]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [29, 20]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 21, 31]},\n      {\"term_id\": \"GO:0005694\", \"supporting_discovery_ids\": [3, 7, 28]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [21, 29]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [0, 3, 7, 10, 28]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [1, 5, 20]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [5, 16, 19, 27, 29]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [11, 18, 29]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [2, 3, 22]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [1, 4]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [29]}\n    ],\n    \"complexes\": [\n      \"PRC1 (Cbx7-Ring1B canonical PRC1)\",\n      \"CBX7-HDAC2 repressive complex\",\n      \"CBX7-SETDB1/EHMT1/EHMT2 complex\",\n      \"CBX7-c-Raf/MEK1/2/CK2-α cytoplasmic signaling complex\"\n    ],\n    \"partners\": [\n      \"RING1\",\n      \"RNF2\",\n      \"HDAC2\",\n      \"SETDB1\",\n      \"EHMT1\",\n      \"EHMT2\",\n      \"TARDBP\",\n      \"KAP1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}